David Fagenbaum
speaker
271 appearances
3 recordings
2 series
first heard Dec 2024
last heard 28 Feb
David Fagenbaum’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.
Appearances
Thank you.
During this remission, I married Caitlin, who's here with us today.
We had two amazing children.
I wrote a book about my journey chasing my cure, which is being turned into a film.
And I joined the faculty at the University of Pennsylvania to continue to chase cures for rare inflammatory diseases and cancers.
And then in 2022, I co-founded EveryCure, a nonprofit organization that's on a mission to unlock the full potential of each and every drug to treat each and every disease that it possibly can.
Over these years, we've advanced 14 repurposed treatments for multiple diseases, saving thousands of lives, like Kyla, who began her freshman year of nursing school after we repurposed a bone marrow cancer drug to save her life, which is now being studied in clinical trials.
And Michael, who walked his son down the aisle on his wedding day after we repurposed a melanoma drug to treat his rare cancer, which is now being used all over the world for that rare cancer.
With every one of these discoveries, all I can think about is how many more life-saving drugs are sitting at our local pharmacies that could be life-saving for patients with diseases today.
Because, see, us humans, we've developed 4,000 drugs for about 4,000 diseases.
But there are over 14,000 diseases that don't have a single approved therapy.
That means that one in 10 of us and our kids will develop a rare disease without any approved treatments.
And many more of us will develop diseases with limited treatment options.
We know that many of these FDA-approved drugs could treat many more of these diseases, and for less than one percent of the cost of new drug development, and way faster.
So why aren't we repurposing drugs?
Well, the short answer is that it's just not profitable to pursue a new use for an existing medicine, especially for a rare disease and the 80% of drugs that are already generic.
It just costs too much to do the clinical trials, and companies can't expect to make back the costs in sales.
Instead, we focus on new drugs for profitable diseases, and no one, not the NIH, not the FDA, not pharma, no one has taken responsibility for systematically unlocking these hidden cures.
Until now.
We're utilizing artificial intelligence to scan across the world's knowledge of all 4,000 drugs and all 18,000 diseases to find the most promising opportunities to save and improve lives.
Showing 181–200 of 271 · page 10 of 14
← Previous
Next →